Glucagon-like peptide-1 receptor activation reduces ischaemic brain damage following stroke in Type 2 diabetic rats by Darsalia, Vladimer et al.
Clinical Science (2012) 122, 473–483 (Printed in Great Britain) doi:10.1042/CS20110374 473
Glucagon-like peptide-1 receptor activation
reduces ischaemic brain damage following
stroke in Type 2 diabetic rats
Vladimer DARSALIA∗, Shiva MANSOURI∗, Henrik ORTS¨ ATER∗, Anna OLVERLING∗,
Nino NOZADZE∗, Camilla KAPPE∗, Kerstin IVERFELDT†, Linda M. TRACY†,
Nina GRANKVIST∗,A ˚ke SJ¨ OHOLM∗ and Cesare PATRONE∗
∗Diabetes Research Unit, Department of Clinical Science and Education, S¨ odersjukhuset, Karolinska Institutet, Stockholm,
Sweden, and †Department of Neurochemistry, Stockholm University, Stockholm, Sweden
ABSTRACT
Diabetes is a strong risk factor for premature and severe stroke. The GLP-1R (glucagon-like
peptide-1 receptor) agonist Ex-4 (exendin-4) is a drug for the treatment of T2D (Type 2 diabetes)
that may also have neuroprotective effects. The aim of the present study was to determine the
efﬁcacy of Ex-4 against stroke in diabetes by using a diabetic animal model, a drug administration
paradigm and a dose that mimics a diabetic patient on Ex-4 therapy. Furthermore, we investigated
inﬂammation and neurogenesis as potential cellular mechanisms underlying the Ex-4 efﬁcacy. A
total of seven 9-month-old Type 2 diabetic Goto–Kakizaki rats were treated peripherally for
4 weeks with Ex-4 at 0.1, 1 or 5 μg/kg of body weight before inducing stroke by transient
middle cerebral artery occlusion and for 2–4 weeks thereafter. The severity of ischaemic damage
was measured by evaluation of stroke volume and by stereological counting of neurons in the
striatum and cortex. We also quantitatively evaluated stroke-induced inﬂammation, stem cell
proliferation and neurogenesis. We show a profound anti-stroke efﬁcacy of the clinical dose of Ex-
4 in diabetic rats, an arrested microglia inﬁltration and an increase of stroke-induced neural stem
cell proliferation and neuroblast formation, while stroke-induced neurogenesis was not affected
by Ex-4. The results show a pronounced anti-stroke, neuroprotective and anti-inﬂammatory effect
of peripheral and chronic Ex-4 treatment in middle-aged diabetic animals in a preclinical setting
that has the potential to mimic the clinical treatment. Our results should provide strong impetus
to further investigate GLP-1R agonists for their neuroprotective action in diabetes, and for their
possible use as anti-stroke medication in non-diabetic conditions.
INTRODUCTION
Stroke is the primary cause of disability in adults and
the third most common cause of death. Stroke is often
associated with comorbid health conditions that increase
theriskandseverityofstroke[1,2].T2D(Type2diabetes)
is one such comorbid disease where premature stroke
represents one of the most common and serious long-
term complications [3–6]. The risk of stroke is increased
2- to 6-fold in patients with T2D [6] with greater risk for
stroke recurrence and higher mortality rate [6,7]. Finally,
a pre-diabetic state with impaired glucose tolerance
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is often detected in stroke patients following hospital
admission, and such patients generally exhibit a poor
prognosis [8,9].
GLP-1R (glucagon-like peptide-1 receptor) agonists
are novel treatments against T2D [10], which may
also have direct neuroprotective effects besides their
gluco-regulatory action. These molecules interact with
the G-protein-coupled GLP-1R and enhance glucose-
dependentinsulinsecretion[11].Exenatide[syntheticEx-
4 (exendin-4)] is a stable GLP-1 analogue isolated from
the saliva of the ‘Gila monster’ lizard [12]. It is resistant
to degradation and is approved in both Europe and the
U.S.A. for the clinical treatment of T2D [11].
GLP-1R is expressed throughout the brain [13,14]
and GLP-1 and Ex-4 can cross the blood–brain barrier
[15]. GLP-1R agonists have been reported to be
neuroprotective [16,17], neurogenic [18,19], enhance
synaptic plasticity [20] and improve different forms of
learning [16,19]. Furthermore, anti-inﬂammatory CNS
(central nervous system) effects of GLP-1 have been
reported [21–23]. Intracerebroventricular administration
of Ex-4 15 min before stroke reduced ischaemic damage
in mice [24]. Intraperitoneal injection of Ex-4 2 h
before ischaemia and 1 h after reperfusion protected
hippocampal CA1 neurons in a global ischaemia model
in gerbils [25]. Finally, acute intravenous administration
of Ex-4 following ischaemia reduced the infarct volume.
However, the neuroprotective effect was lost if Ex-4 was
administered 3 h after stroke [26]. These studies were
performed in young healthy non-diabetic mice.
AlthoughtheeffectsofGLP-1Ractivationinthebrain
are promising, more research is needed to understand
the mechanisms behind its action and whether GLP-1R
activation is effective in the diabetic brain.
In the present study, we tested the anti-stroke efﬁcacy
of Ex-4 in diabetes by using middle-aged diabetic GK
(Goto–Kakizaki) rats. The GK rat is a non-obese Wistar
substrain,whichspontaneouslydevelopsT2Dearlyinlife
[27] and where Ex-4 treatment reduces hyperglycaemia
[28].
MATERIALS AND METHODS
Ex-4 bioactivity assay
To ascertain the bioactivity of Ex-4 (kindly provided by
Amylin), insulin secretion was measured from islets of
Langerhans isolated from non-diabetic male Wistar rats.
Batches of 15 islets per groupwere maintained for 30 min
at 37◦C in a buffer consisting of 3 or 20 mM glucose,
125 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2, 1.3 mM
CaCl2and 25 mM Hepes, titrated to pH 7.4 with NaOH
and supplemented with 1 mg/ml BSA (fraction V; Roche
Diagnostics)with/without10 nMEx-4.Afterincubation,
aliquots of buffer were frozen pending analyses of
released insulin by ELISA (Mercodia).
Figure 1 Experimental design and drug administration
paradigm
Animals and experimental groups
A total of 42 7–9-month-old male diabetic GK rats were
used. All experiments were conducted according to the
‘Guide for the Care and Use of Laboratory Animals’
published by U.S. National Institutes of Health (NIH
publication no. 85-23, revised 1985) and approved by the
regional ethics committee for animal experimentation.
Before the start of the Ex-4/PBS treatments, baseline
fasting blood glucose concentrations were measured and
the animals were assigned to the different treatment
groups so that mean blood glucose values were
equalized. Treatment groups thus created were tested
for normality using the D’Agostino and Pearson
omnibus normality test. All rats received intraperitoneal
injections of Ex-4 [0.1, 1 or 5 μg/kg of bw (body
weight) (n=10)] or PBS (n=12) for 4 weeks twice
daily before being subjected to stroke. Ex-4 and PBS
injections were continued for another 2 or 4 weeks
following the stroke. To assess neurogenesis, all rats
received daily intraperitoneal injections of the thymidine
analogue BrdU (bromodeoxyuridine; 50 mg/kg of bw)
for 2 weeks following stroke. Rats were killed for
immunohistochemical analyses at 2 or 4 weeks after
stroke. The experimental design is illustrated in Figure 1.
MCAO [MCA (middle cerebral artery)
occlusion]
MCAO is a stroke animal model that closely resembles
the most common form of human stroke [29]. Rats
were anaesthetized by spontaneous inhalation of 1.5%
isoﬂuorane through a snout-mask. Body temperature
was maintained at 37–38◦C using a heating pad. Stroke
was induced by the intraluminal ﬁlament technique
[29]. Brieﬂy, common and external carotid arteries were
ligated, and the internal carotid artery was temporarily
closed. A monoﬁlament was advanced through the in-
ternalcarotidarterytotheoriginoftheMCA,thewound
wasclosedandtheanimalwasallowedtowakeupandwas
placed in its cage. After 90 min of occlusion, the animals
wereanaesthetizedagainandtheﬁlamentwaswithdrawn.
The surgeon performingthe operation was blinded to the
treatment groups.
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Immunocytochemistry
Animals were deeply anaesthetized and perfused
transcardially with 4% (w/v) paraformaldehyde. The
brains were extracted and submersed in 20% sucrose
in phosphate buffer overnight. Then 40-μm-thick
coronal sections were cut using sliding microtome and
stained as free-ﬂoating sections. The following primary
antibodies were used: mouse anti-Ki67 (1:200 dilution;
Novocastra), a marker of cell proliferation; goat anti-
DCX(doublecortin)(1:400dilution;SantaCruzBiotech-
nology), a marker for migrating neuroblasts; mouse anti-
NeuN (1:100 dilution; Millipore), a neuronal marker;
rabbit anti-Iba1 (1:1000 dilution, Wako Chemicals), a
marker for microglia; mouse anti-ED1 (1:200 dilution;
Serotec), a marker of activated microglia; rat anti-BrdU
(1:200 dilution; Santa Cruz Biotechnology), to assess
neurogenesisincombinationwithNeuN;andrabbitanti-
GLP-1R (1:50 dilution; Abcam). In the sections stained
forGLP-1R,DAPI(4 ,6-diamidino-2-phenylindole)was
used to visualize all of the cells. Sections were incubated
with primary antibodies overnight at 4◦C in phosphate
buffer containing 3% appropriate serum and 0.25%
Triton X-100. Primary antibodies were detected by use
ofappropriateﬂuorescentCy3(indocarbocyanine)-,Cy2
(carbocyanine)- (both from Jackson ImmunoResearch)
or biotin-conjugated (Vector) secondary antibodies
(1:200 dilution). Sections were incubated with secondary
antibodies for 2 h at room temperature (approx. 21◦C)
in phosphate buffer containing 3% of the appropriate
serum and 0.25% Triton X-100. For chromogenic
visualization, biotinylated secondary antibodies, avidin–
boitin complex (ABC kit; Vector) and diaminobenzidine
were used.
Tissue damage evaluation and cell
quantiﬁcation
Tissue damage evaluation and cell counting were
performed by an investigator blinded to the experimental
groups. For tissue damage evaluation, the NeuN-labelled
tissue sections were displayed live on the computer
monitor and the area of contralateral hemisphere and
the area of the intact ipsilateral tissue were measured in
every section containing stroke damage using NewCast
(Visiopharm) software. To compensate for the stroke-
inducedmorphologicaltissuechanges,theinfarctvolume
was calculated by subtracting the volume of remaining
tissue in the ipsilateral hemisphere from the volume of
the contralateral hemisphere.
Immunoreactive cells were counted using either a
computerized non-biased setup for stereology, driven
by NewCast software, or by using an Olympus
BX40 epiﬂuorescence/light microscope. The number of
neurons (NeuN) and microglia (Iba1 and ED1) cells
was quantiﬁed using the optical fractionator method
[31,32]. Brieﬂy, brain sections were displayed live on the
computermonitorandthestriatumandcortexdelineated
at low magniﬁcation. Quantiﬁcations were performed
using a ×100 oil-immersion lens with numeric aperture
of 1.30 or a ×40 dry lens with numeric aperture of
0.75. Ten evenly spaced sections in parallel-cut series
through the entire striatum were included. Random
sampling was carried out using the counting frame,
which systematically was moved at predeﬁned intervals
so that ∼200 immunoreactive cells were counted. The
total number of cells was estimated according to the
optical fractionator formula [31,32].
For evaluation of SVZ (subventricular zone) cell
proliferation, SVZ cells immunoreactive for Ki67 were
counted. DCX is a marker for newly produced
neuroblasts from neurogenic brain areas and DCX-
positive cells have been shown to migrate into the
ischaemicstriatum[33].Thereforeneuroblastproduction
was quantiﬁed by counting cells positive for DCX
in stroke-damaged striatum. NeuN is a ubiquitous
nuclear marker for mature neurons. Thus, neurogenesis
was assessed by counting NeuN/BrdU-positive cells
in stroke-damaged striatum. These quantiﬁcations were
performedinthreeevenlyspaced(400 μM)brainsections
onthesideipsilateraltostroke,startingat0.7 mmanterior
to Bregma.
Statistics
Statistical analyses were performed using one-way
or two-way ANOVA, followed by Bonferroni’s or
Dunnet’spost-hoctest.Differencesbetweengroupswere
considered statistically signiﬁcant when P<0.05. Results
are presented as means+ −S.E.M.
RESULTS
Ex-4 reduces hyperglycaemia in GK rats
The bioactivity of Ex-4 was shown as its efﬁcacy
to augment several fold the glucose-induced insulin
secretion in islets of Langerhans isolated from adult non-
diabetic rats (results not shown). Treatment with Ex-4
slightlyreducedglycaemiainGKrats,althoughthiseffect
did not attain statistical signiﬁcance in the groups treated
with 0.1 and 1 μg/kg of bw. Only the group treated with
Ex-4 at 5 μg/kg of bw showed a statistically signiﬁcant
reduction in glycaemia after 2 and 4 weeks of treatment
(Figures 2A–2D). Animals were fasted for 3 h before
blood glucose measurements were performed.
GLP-1R is expressed by neurons in the
brain of diabetic rats
To assess GLP-1R expression in the brain, we
immunostained brain sections for GLP-1R. The results
showed a widely dispersed expression of GLP-1R
throughout the brain which co-localized with NeuN-
positive-neurons (Figure 3).
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Figure 2 Ex-4 effects on glycaemia in GK rats
(A–D) Fasted blood glucose levels in GK rats treated with PBS (n=12), or EX-4
at 0.1 (n=10), 1 (n=10) or 5 μg/kg of bw (n=10) for 4 weeks before
inducing a stroke. Bars represent means+ −S.E.M. ∗P <0.05 and ∗∗P <0.01
compared with week 0 using one-way ANOVA, followed by Bonferroni’s post-hoc
analysis.
Ex-4 exhibits dose-dependent anti-stroke
efﬁcacy
In order to determine the potential anti-stroke efﬁcacy
mediated by Ex-4, the measurement of infarct volume
was assessed at both 2 and 4 weeks after stroke. Since
no difference was recorded between 2 and 4 weeks after
stroke between the treatment groups, results from 2- and
4-week time points were pooled. The measurement of
the infarct volume revealed that treatment with Ex-4 at
5 μg/kg of bw resulted in a signiﬁcant reduction of tissue
damage after stroke (Figures 4A, 4C, and 4D). Although
not statistically signiﬁcant, the treatment with Ex-4 at 0.1
and 1 μg/kg of bw showed a noticeable trend towards a
reduction of ischaemic tissue damage (Figure 4D).
In order to assess the neuroprotective effect of
Ex-4 with greater accuracy than infarct volume
measurement, NeuN-positive neurons were quantiﬁed
in both stroke-damaged striatum and cortex using
the optical fractionator method (see the Materials and
methods section). As for the volume measurements,
no difference was recorded in the number of surviving
neurons between 2 and 4 weeks after stroke between the
treatment groups. Thus results from 2- and 4-week time
points were pooled. Results in Figure 4(E) show that,
following a stroke induced by MCAO, the least amount
of neurons remained in the stroke-damaged striatum
and cortex of the PBS-treated group. Furthermore, in
the two groups of animals treated with Ex-4 at 0.1 and
1 μg/kg of bw, the activation of GLP-1R resulted in
a statistically signiﬁcant effect above control with an
increased number of surviving neurons in the stroke-
damagedstriatumandcortex(Figure4E).Treatmentwith
Ex-4 at 5 μg/kg of bw further increased the number of
surviving neurons compared with both PBS and the two
lower doses of Ex-4 (Figure 4E). When neuronal survival
was evaluated separately in the striatum and cortex,
the neuronal quantiﬁcations showed that a statistically
signiﬁcant neuroprotective effect in striatum was only
achieved with Ex-4 at 5 μg/kg of bw, although a dose-
dependent trend was also noticeable with the two lower
Ex-4 doses (Figure 4F). This neuroprotective effect was
much stronger in the cortex, where Ex-4 treatment at 0.1
and 1 μg/kg of bw also resulted in statistically signiﬁcant
neuroprotection (Figure 4G).
Ex-4 treatment signiﬁcantly reduces
microglia inﬁltration after stroke, but has
a marginal effect on microglia activation
To evaluate the magnitude of microglia inﬁltration,
reﬂecting inﬂammatory levels, Iba1-immunoreactive
cells were counted using the optical fractionator method
(see the Materials and methods section). At 2 weeks
after stroke, the number of Iba1-positive microglial
cells within the stroke-damaged hemisphere (cortex plus
striatum;Figure5A)andincortexandstriatumseparately
(Figures 5C and 5E) was similar in the PBS-treated
and Ex-4-treated groups. However, at 4 weeks after
stroke, the number of Iba1-positive cells in stroke-
damaged hemisphere was signiﬁcantly different between
the groups treated with Ex-4 and PBS (Figure 5B).
When we evaluated microglia inﬁltration at 4 weeks in
the ipsilateral striatum and cortex separately, it became
apparent that the Ex-4 treatment had no effect on
microglia inﬁltration in the striatum (Figure 5D), while a
Figure 3 GLP-1R expression in the cortex of the GK rat brain
(A) DAPI staining (general cell marker); (B) neurons positive for NeuN (neuro-speciﬁc marker); (C) GLP-1R-positive cells; (D) merged channels for NeuN and GLP-1R.
Arrowheads indicate cells positive for DAPI, NeuN and GLP-1R respectively. Images were taken using a ×40 dry lens with 0.75 numeric aperture and ColorView II FW
digital camera driven by the CellA imaging software. Brightness/contrast was adjusted and ﬁnal images resized using Adobe Photoshop software. (D) Scale bar, 50 μm.
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Figure 4 Neuroprotective effect of Ex-4
(A–C) Photomicrographs of representative ischaemic damage after treatment with PBS, or Ex-4 at 0.1 or 5 μg/kg of bw. Dotted lines outline the ischaemic damage.
(C) Scale bar, 2 mm. (D) Volume of the infarct. (E–G) Stereological quantiﬁcation of NeuN-positive cells in stroke-damaged striatum and cortex. Groups, PBS (n=12),
or EX-4 at 0.1 (n=10), 1 (n=10) or 5 (n=10) μg/kg of bw. Values are means+ −S.E.M. ∗P <0.05 and ∗∗P <0.01 between groups using one-way ANOVA,
followed by Bonferroni’s post-hoc test.
statistically signiﬁcant effect was recorded in the cortex
between each of the Ex-4 treated groups and PBS
(Figure 5F).
To assess microglia activation, ED1-positive cells were
quantiﬁed in a similar manner by using the optical
fractionator method. As for Iba1, at 2 weeks after
stroke, the number of ED1-positive microglial cells was
similar in all experimental groups, both in striatum
and cortex separately or pooled together (Figures 5I,
5K and 5M). At 4 weeks after stroke, the number of
ED1-positive cells also did not decrease signiﬁcantly
(Figures5J,5Land5N).However,astrongtrendtowards
a reduction of the number of ED1-positive microglial
cells in the group treated with Ex-4 at 5 μg/kg of
bw was observed in striatum and cortex both pooled
together or when analysed separately (Figures 5J, 5L
and 5N).
Ex-4 treatment increases stem cell
proliferation and neuroblast formation
without affecting stroke-induced
neurogenesis
The SVZ of the lateral ventricle and the hippocampal
dentate gyrus are the two brain areas in which adult
neurogenesis occurs [34]. To study the effect of Ex-4
treatment on stroke-induced neurogenesis, all animals
were given daily injections of the thymidine analogue
BrdU for 2 weeks following MCAO. Brains were
analysed 2 or 4 weeks after stroke (Figure 1).
Ki67-expressing cells were counted to evaluate
stem/progenitor cell proliferation in the SVZ of the
brain. The results show that, at 2 weeks after stroke,
Ex-4-treated animals showed 2-fold greater number of
proliferating cells in the SVZ as compared with the
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Figure 5 Magnitude of brain inﬂammation following Ex-4 treatment at 2 and 4 weeks after stroke
(A, B) Stereological quantiﬁcation of Iba-positive microglial cells in the stroke-damaged hemisphere at 2 (A) and 4 (B) weeks after MCAO. (C, D) Stereological
quantiﬁcation of Iba1-positive microglial cells in the stroke-damaged striatum at 2 (C) and 4 (D) weeks after stroke. (E, F) Stereological quantiﬁcation of Iba-positive
microglial cells in the stroke-damaged cortex at 2 (E) and 4 (F) weeks after MCAO. (G, H) Representative images of Iba1 immunoreactivity in the groups receiving PBS
( G )o rE x - 4a t5μg/kg of bw (H) at 4 weeks after stroke. (I, J) Stereological quantiﬁcation of ED1-positive microglial cells in the stroke-damaged hemisphere at 2 (I)
and 4 (J) weeks after stroke. (K, L) Stereological quantiﬁcation of ED1-positive microglial cells in the stroke-damaged striatum at 2 (K) and 4 (L) weeks after MCAO.
(M, N) Stereological quantiﬁcation of ED1-positive microglial cells in the stroke-damaged cortex at 2 (M) and 4 (N) weeks after stroke. (O, P) Representative images
of ED1 staining in the group treated with PBS (O) and Ex-4 at 5 μg/kg of bw (P) at 4 weeks after stroke. (P) Scale bar, 2 mm. Groups at 2 weeks, PBS (n=6)
or Ex-4 at 0.1 (n=5), 1 (n=5) and 5 (n=5) μg/kg of bw. Groups at 4 weeks, PBS (n=6) or Ex-4 at 0.1 (n=5), 1 (n=5) and 5 (n=5) μg/kg of
bw. Values are means+ −S.E.M. ∗P <0.05 between groups using one-way ANOVA, followed by Dunnet’s post-hoc test.
PBS group (Figures 6A, 6C and 6E), with no statistical
differences between the different Ex-4 doses (Figure 6A).
However, 4 weeks after stroke, no difference in the
number of Ki67-positive cells between PBS- and Ex-4-
treated groups was recorded (Figures 6A, 6D and 6F).
Stroke-induced neuroblast production was evaluated
by quantifying the number of DCX-positive cells in the
striatum. The DCX-positive neuroblast quantiﬁcation
revealed that, at 2 weeks after stroke, Ex-4 treatment
led to a 1.5-fold increase in neuroblast production
compared with the PBS-treated group (Figures 6B, 6G
and 6I). However, at 4 weeks after stroke, no difference
in neuroblast production between PBS- and Ex-4-treated
animals was recorded (Figures 6B, 6H and 6J).
Double labelling for the neuronal marker NeuN and
the proliferation marker BrdU was used to identify
mature neurons that were generated after stroke in
striatum. At 2 weeks after stroke, the number of
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Figure 6 Stroke-induced neural stem/progenitor cell proliferation and neurogenesis in Ex-4-treated GK rat SVZ and striatum
(A) Number of Ki67-positive cells in SVZ ipsilateral to stroke at 2 and 4 weeks after stroke. (B) Number of DCX+ neuroblasts at 2 and 4 weeks after stroke in the
stroke-damaged striatum. White and black bars represent animals killed at 2 and 4 weeks respectively. (C, D) Representative images of Ki67 immunoreactivity in the
ipsilateral SVZ of PBS-treated rats at 2 and 4 weeks after stroke respectively. (E, F) Representative images of Ki67 immunoreactivity in the ipsilateral SVZ of rats
treated with Ex-4 at 5 μg/kg of bw at 2 and 4 weeks after stroke respectively. (F) Scale bar, 200 μm. (G, H) Representative images of DCX immunoreactivity in the
ipsilateral striatum of PBS-treated rats at 2 and 4 weeks after stroke respectively. (I, J) Representative images of DCX immunoreactivity in the ipsilateral striatum of
rats treated with Ex-4 at 5 μg/kg of bw at 2 and 4 weeks after stroke respectively. (J) Scale bar,100 μm. (K) Number of NeuN/BrdU+ neurons in stroke-damaged
striatum at 2 (white bars) and 4 (black bars) weeks after stroke. (L–N) Photomicrographs of a NeuN/BrdU+ neuron in stroke-damaged striatum. (L) NeuN, (M) BrdU
and (N) merged channels showing double staining. (N) Scale bar, 20 μm. Groups at 2 weeks, PBS (n=6) or Ex-4 at 0.1 (n=5), 1 (n=5 )a n d5( n=5) μg/kg
of bw. Groups at 4 weeks, PBS (n=6) or Ex-4 at 0.1 (n=5), 1 (n=5 )a n d5( n=5) μg/kg of bw. Values are means+ −S.E.M. ∗P <0.05 between groups
using two-way ANOVA, followed by Bonferroni’s post-hoc test. w, weeks.
NeuN/BrdU-positive neurons was similar in both
PBS- and Ex-4-treated groups (Figure 6K). At 4 weeks
after stroke, the number of NeuN/BrdU-positive
neurons increased 2-fold in all groups without any
differencesbetweenthePBS-andtheEx-4-treatedgroups
(Figure 6K).
Similar quantiﬁcations were performed in the
subgranular zone and granule cell layer of the dentate
gyrus of the hippocampus. In this case, Ex-4 treatment
had no detectable effect on either cell proliferation or
neurogenesis (results not shown).
DISCUSSION
In the present study, we show the anti-stroke efﬁcacy
of Ex-4 in a preclinical setting that mimics the clinical
situation. Although successful in animal models, anti-
stroke treatment strategies based on early intervention
with neuroprotective drugs have not yet proven their
efﬁcacy in the clinic [35,36]. On the other hand,
therapeutic strategies during the later and chronic
phase of stroke have been largely unsuccessful both in
preclinical experiments and clinical trials [36–38]. This
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failure is likely due to two main factors. First, principal
differences between the research animal models and
typical stroke patients. The majority of stroke patients
are elderly [39], where comorbidities such as diabetes
and hypertension are common [2,35]. By contrast, in
most of the preclinical experiments the efﬁcacy of
drugs is tested on animals that are both young and
healthy. It has been calculated that to date, for six
drugs reviewed systematically, only 10% of publications
which studied the efﬁcacy of these drugs had used
animals with hypertension or diabetes, and none of
the experiments reported efﬁcacy in aged animals [35].
Secondly, preclinical drug administration paradigms are
often not relevant for the clinical situation. For example,
in many cases the preclinical efﬁcacious doses of these
drugs vastly (several orders of magnitude) differed
from doses used in clinical practice [40]. Therefore, the
successful implementation of preclinical achievements
is largely dependent on how closely the experimental
paradigms match the likely clinical scenario.
In the present study, we have evaluated the anti-
stroke efﬁcacy of the GLP-1R analogue Ex-4. The
neuroprotective effect of Ex-4 administered immediately
or within an hour after ischaemia in non-diabetic adult
micehasbeenpreviouslydemonstrated[25,26].However,
the neuroprotective effect was not seen when Ex-4 was
administered after a 3 h delay [26]. These results are
clearly interesting and demonstrate GLP-1R-mediated
acute neuroprotection. However, their applicability to
the clinical setting is remote due to the relatively short
effective intervention time-window (up to 1 h) and the
Ex-4 doses employed that were up to 100 times higher
(10 μg/kg of bw) when compared with the clinical dose
[26].
To closely simulate the way Ex-4 is used in clinical
practice, we have used middle-aged Type 2 diabetic GK
rats, among which one group was treated with Ex-4
at 0.1 μg/kg of bw, which corresponds to the clinical
dose that is used in Type 2 diabetic patients. Since Ex-
4 is a marketed drug for the treatment of T2D, our
rationale was to mimic the clinical setting of Type 2
diabetic patients on Ex-4 treatment, where the peripheral
and chronic administration of Ex-4 will likely occur
both before and after stroke. Therefore, we have treated
GK rats in a similar manner and administered clinically
relevant doses of Ex-4 for several weeks both before and
after stroke. We demonstrate here, for the ﬁrst time, anti-
stroke efﬁcacy of Ex-4 in a preclinical setting that mimics
the clinical situation.
Whenweevaluatedthetissuedamagebymeasuringthe
infarct volume, only the highest dose of Ex-4 (5 μg/kg of
bw)showedastatisticallysigniﬁcanteffectincomparison
withthecontrolgroup,whereasthetwolowerEx-4doses
(0.1 and 1 μg/kg of bw) produced a noticeable but not
statistically signiﬁcant trend towards reduction of the
infarctvolume.Closerexaminationrevealed‘thinning’of
neuronal density and ‘patchy’ cell loss in these animals as
opposed to the more severe cell loss in the control group.
The quantiﬁcation of surviving NeuN-positive neurons
using the optical fractionator method revealed that when
counts from striatum and cortex were combined, the two
lower doses of Ex-4 signiﬁcantly increased the neuronal
survival (indicated by increased neuronal counts). Since
infarct volume measurement does not account for
neuronal loss in tissue surrounding the infarct, we
suggest that this type of assessment is an accurate
and precise addition for evaluating stroke damage and
neuronalsurvival.Unlikethemeasurementsoftheinfarct
volume, which dramatically changes depending on the
time after stroke and may lead to misinterpretation
of the results [42,43], the stereological quantiﬁcation of
surviving neurons the using optical fractionator method
provides accurate information and helps in avoiding such
pitfalls.
The Ex-4-mediated efﬁcacy was dose-dependent, with
5 μg/kg of bw being the most effective dose in the study.
Ex-4 has been reported to cross the blood–brain barrier
in normal mice [15] and GLP-1R is expressed on NeuN-
positive neurons.
Although the anti-stroke effect mediated by Ex-4 was
foundtobedose-dependent,itwasnotlinearbetweenthe
three administered doses. One possibility to explain this
non-linearity is that Ex-4 at the two lower doses may act
via the known GLP-1R, while the neuroprotective effect
mediated by the highest dose of Ex-4 is also occurring via
a GLP-1R-independent pathway recently described [44].
Linearity may also not be expected considering that the
incretin effect by Ex-4 occurs on top of already existing
GLP-1 levels in the blood. Finally, although Ex-4 can
pass the blood–brain barrier [15], it is hard to predict
what amount of Ex-4 can reach both striatum and cortex.
The neuroprotective effect of Ex-4 was stronger in
the cortex than in the striatum. To investigate whether
this effect is due to differences in GLP-1R expression in
cortex and striatum, quantitative studies will have to be
performed at earlier time points than the ones used in our
study thus better targeting the neuroprotective window
(hours to few days after MCAO). While the possibility
that the cortical and striatal neurons react differently
to Ex-4 treatment cannot be ruled out, this difference
is most likely due to the characteristics of the stroke
model that we have employed. In this model, ischaemic
damage originates in the striatum and then spreads across
the overlaying cortex depending on the duration of the
MCAO. Thus, as cortex contains more ischaemic
penumbral area, the neuroprotective intervention can be
more effective.
Ex-4 stimulates insulin secretion [45] and a number of
previous studies have reported decreased ischaemic brain
injury when hyperglycaemic levels of diabetic animals
were normalized using insulin [46,47]. In our study,
however, the treatment with Ex-4 at 0.1 and 1 μg/kg of
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bw signiﬁcantly reduced stroke injury without showing
a signiﬁcant impact on hyperglycaemia (Figures 2B and
2C). Thus we suggest that, in our case, the reduction
in neuronal damage mediated by Ex-4 at 0.1–1 μg/kg
of bw is largely independent of glycaemic effects. Only
the treatment with Ex-4 at 5 μg/kg of bw resulted in a
signiﬁcant reduction in glycaemia (Figure 2D), although
these animals still remained hyperglycaemic. This dose of
Ex-4wasalsothemosteffectiveinreducingtheischaemic
brain injury, and therefore a partial contribution of the
Ex-4-mediated glucose lowering to the reduction of
the ischaemic damage cannot be ruled out. To entirely
excludethepossibilitythatEx-4inducesneuroprotection
by lowering glucose, future studies will be done using
blood glucose-lowering drugs, titrated to achieve the
same glycaemic effects as Ex-4, in head-to-head com-
parisons. Interestingly, and in support of our ﬁndings,
Teramoto et al. [26] recently reported that the anti-
stroke efﬁcacy by GLP-1R activation in non-diabetic
mice occurred with unchanged insulin levels, suggesting
that its CNS effects are not due to changes in glycaemia.
At 2 weeks after stroke, all groups showed similar
numbers of Iba-positive microglial cells in the injured
brain hemisphere. However, at 4 weeks following stroke,
signiﬁcantly fewer Iba1-positive microglial cells were
detected in the cerebral cortex of Ex-4-treated groups.
The inﬂammation process in the brain after stroke may
last for several weeks and is believed to have both
beneﬁcial and detrimental effects that largely depend
on the time after the stroke onset [48,49]. As evident
from Figures 5(A), 5(B), 5(E) and 5(F), the difference
in Iba1-positive numbers at 4 weeks is mainly attributed
to the increase of microglia inﬁltration from 2 weeks
and onwards in the PBS group, whereas it remained
largely unchanged in Ex-4-treated groups. We interpret
our results as the Ex-4 treatment after 4 weeks had
halted the microglia inﬁltration, but had not reduced
its magnitude compared with the 2 weeks time point.
Furthermore, since the change in microglia inﬁltration
after Ex-4 treatment did not correlate either with the
size of the ischaemic lesion or the stroke-induced stem
cell proliferation and neurogenesis, it is unclear whether
the modulation of microglia inﬁltration by Ex-4 has
any signiﬁcant impact on the ischaemic damage and
stroke-induced neurogenesis. Although it is possible
that the decreased microglia inﬁltration could inﬂuence
neurogenesis at later time-points, new experiments using
these later-time points will be needed to answer this
question.
Obesity and diabetes impair adult neurogenesis and
animal studies have shown decreased neurogenesis
in diabetic animal models [50–54]. Stroke induces
neurogenesis in both rodents and humans [33,55–57].
However, it is known that the great majority of the new-
born neuroblasts induced by stroke do not reach the
mature state due to poor survival [58]. Since our previous
work has shown that Ex-4 enhances neurogenesis in
non-diabetic rodents [18,19], in this work we studied
whether Ex-4 had the potential to enhance stroke-
induced neurogenesis and/or to promote survival of
the newly generated neurons in the diabetic brain.
Our results show that Ex-4 treatment signiﬁcantly
increased stem/progenitor cell proliferation in the SVZ
and neuroblast production in the striatum. However, this
effectwasonlynoticeableat2 weeksafterstroke,whereas
no differences between the groups were observed after
4 weeksofEx-4treatment.Thekineticsofstroke-induced
neural stem/progenitor cell proliferation in GK rats have
not been yet characterized. However, it is conceivable
that at this later time point, any proliferative effect of
Ex-4 treatment may be masked by the proliferative effect
induced by stroke.
Although at 2 weeks after stroke, Ex-4 treatment
increased stem cell and neuroblast proliferation, this
treatment did not result in any increase in the generation
of mature neurons. Both at 2 and 4 weeks after stroke
all groups showed similar numbers of NeuN/BrdU-
positive neurons, although the number of NeuN/BrdU-
positive neurons at 4 weeks was 2-fold higher compared
with 2 weeks in both PBS and Ex-4 treatment groups.
This is most likely due to neuroblast differentiation
[33]. Thus, although a greater number of proliferating
cells and neuroblasts at 2 weeks after stroke in the
Ex-4 treated groups did not result in an increase in
neuronal differentiation, our results provide evidence
that Ex-4 indeed stimulates the formation of new brain
cells following stroke. Whether these Ex-4-induced
proliferating cells can contribute to the reduction
of the ischaemic damage remains to be investigated.
However, future therapeutic strategies based on the
combination of Ex-4 with neuro-surviving factors, might
have the potential to increase the survival and neuronal
differentiation of these newly generated cells.
In conclusion, we report here a pronounced anti-
stroke, neuroprotective and anti-inﬂammatory effect of
peripheral and chronic Ex-4 treatment in middle-aged
diabetic animals in a preclinical setting that has the
potential to mimic the clinical treatment conditions. Our
resultsarestrongmotivatingfactorstofurtherinvestigate
GLP-1R agonists for their neuroprotective action in
diabetes, as well as for their possible use as anti-stroke
therapies in non-diabetic conditions.
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